| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap |
NCT04781335: "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation" |
|
|
| Recruiting | 4 | 50 | US | Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID) | The Eye Institute of West Florida, EyePoint Pharmaceuticals, Inc. | Cataract | 06/21 | 08/21 | | |
NCT06497699: A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery |
|
|
| Completed | 4 | 263 | RoW | Dexycu | Ocumension Therapeutics (Shanghai) Co., Ltd | Inflammation, Cataract | 07/23 | 12/23 | | |
NCT05191706: Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract |
|
|
| Recruiting | 4 | 60 | US | Dexamethasone, Prednisolone Acetate Ophthalmic | EyePoint Pharmaceuticals, Inc. | Cataract | 01/25 | 02/25 | | |
NCT06429306: Study of Dexycu in Treating Intraocular Inflammation |
|
|
| Completed | 3 | 285 | RoW | Dexycu, Investigational product, Placebo | Ocumension Therapeutics (Shanghai) Co., Ltd | Inflammation, Cataract | 11/23 | 04/24 | | |
NCT05550363: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) |
|
|
| Withdrawn | 3 | 150 | NA | Dexycu, Placebo/Vehicle | EyePoint Pharmaceuticals, Inc. | Cataract | 09/23 | 09/23 | | |
NCT05550350: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery |
|
|
| Not yet recruiting | 3 | 150 | NA | Dexycu, Placebo/Vehicle | EyePoint Pharmaceuticals, Inc. | Cataract | 04/24 | 04/24 | | |
SELVEDge, NCT05530421: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 2 | 33 | US | Selinexor, Xpovio, Venetoclax, Venclexta, Venclyxto, Dexamethasone, Decadron, Ozurdex, Dexycu | University of Miami, Karyopharm Therapeutics Inc | Relapsed and Refractory Multiple Myeloma | 03/26 | 03/28 | | |